

# Journal of Visualized Experiments

## The Replica Set method: a high-throughput approach to quantitatively measure *Caenorhabditis elegans* lifespan

--Manuscript Draft--

<b>Article Type:</b>	Methods Article - JoVE Produced Video
<b>Manuscript Number:</b>	JoVE57819R2
<b>Full Title:</b>	The Replica Set method: a high-throughput approach to quantitatively measure <i>Caenorhabditis elegans</i> lifespan
<b>Keywords:</b>	Aging; lifespan; healthspan; survival analysis; <i>Caenorhabditis elegans</i> ; high-throughput; statistical analysis of quantitative phenotypes; software
<b>Corresponding Author:</b>	Andrew Samuelson University of Rochester Medical Center Rochester, NY UNITED STATES
<b>Corresponding Author's Institution:</b>	University of Rochester Medical Center
<b>Corresponding Author E-Mail:</b>	andrew_samuelson@urmc.rochester.edu
<b>First Author:</b>	Adam Benjamin Cornwell
<b>Other Authors:</b>	Adam Benjamin Cornwell Jesse Llop Peter Salzman Juilee Thakar
<b>Author Comments:</b>	
<b>Additional Information:</b>	
<b>Question</b>	<b>Response</b>
If this article needs to be "in-press" by a certain date, please indicate the date below and explain in your cover letter.	

DEPARTMENT OF BIOMEDICAL GENETICS

---

Andrew Samuelson, Ph.D.  
Research Associate Professor



March 13, 2018

Vineeta Bajaj, Ph.D.  
Review Editor

[JoVE](#)

617.674.1888

RE: manuscript, JoVE57819

Dear Dr. Bajaj, Ph.D.

Thank you for your continued consideration of our manuscript entitled: "The Replica Set method: a high-throughput approach to quantitatively measure *Caenorhabditis elegans* lifespan" for publication in JoVE. We thank the editors for their time in facilitating the conversion of our manuscript to a format suitable for JoVE. We appreciate their guidance, and in the revised manuscript we have attempted to address all of the critiques. We hope the manuscript is now suitable for acceptance in JoVE.

In the revised manuscript we have added a paragraph to the introduction that explains in some detail how feeding based RNAi is achieved in *C. elegans*. There was some confusion by the editor as to how RNAi works, which is reasonable for anyone unfamiliar with *C. elegans* functional genomics. Additionally we have expanded the protocol on hypochlorite treatment for synchronizing animals at the start of a lifespan experiment and moved to discussion other options for synchronization. Similarly we have stream-lined the protocol portion for the use of FUdR as a method to prevent progeny production and expanded our discussion accordingly. We provide additional point by point responses in the detailed response to the critique below.

Thank you again for your time and consideration of our manuscript. We look forward to hearing from you.

Sincerely,

A handwritten signature in black ink, appearing to read "Andrew V. Samuelson". The signature is fluid and cursive, with a long horizontal stroke at the end.

Andrew V. Samuelson

## **Detailed response to the critique.**

*1. The editor has formatted the manuscript as per journal's style. Please retain the same.*

We have maintained the formatting during revising.

*2. Please ensure that all text in the protocol section is written in the imperative tense as if telling someone how to do the technique (e.g., "Do this," "Ensure that," etc.). The actions should be described in the imperative tense in complete sentences wherever possible. Avoid usage of phrases such as "could be," "should be," and "would be" throughout the Protocol. Any text that cannot be written in the imperative tense may be added as a "Note." However, notes should be concise and used sparingly. Please include all safety procedures and use of hoods, etc.*

We have made additional revisions to address this, with particular attention to passages that were alluded to by the editor in comments.

*3. The Protocol should contain only action items that direct the reader to do something. Please move the discussion about the protocol to the Discussion.*

We have made these changes as suggested in the new revision. Specifically, in the revised manuscript protocol section we now outline chronological synchronization through the use of hypochlorite treatment and preventing progeny through the addition of FUDR. We have expanded our discussion to include other ways to synchronize animals, and other methods to handle the issue of progeny.

*4. The Protocol should be made up almost entirely of discrete steps without large paragraphs of text between sections. Please also ensure that there is enough detail in each step to supplement the actions seen in the video so that viewers can easily replicate the protocol.*

Longer passage have been trimmed, or broken down into further steps where possible.

*5. Please remember that the protocol cannot be more than 10 pages in length with all the formatting and headings and spacings.*

We were not previously aware that the page length limit included whitespace. We have heavily edited the protocol section to restrict the page length to 10 pages.

*6. Please also check the highlights to not be more than 2.75 pages in length.*

Similarly, our estimate of the length was not including whitespace previously, so we have changed the highlighted selections accordingly. In the revised manuscript only two pages of text are highlighted.

*7. Please obtain explicit copyright permission to reuse any figures from a previous publication. Explicit permission can be expressed in the form of a letter from the editor or a link to the editorial policy that allows re-prints. Please upload this information as a .doc or .docx file to your Editorial*

*Manager account. The Figure must be cited appropriately in the Figure Legend, i.e. "This figure has been modified from [citation]."*

We have looked into copyright permission for the relevant figures. Neither figure that has previously been published requires explicit permission for reuse.

The contents of Figure 4 were published under open access at *PLOS Genetics*, which uses the Creative Commons Attribution (CC BY) license (as per <http://journals.plos.org/plosgenetics/s/licenses-and-copyright>).

The contents of Figure 5 were published in *Genes and Development*. Articles published in *Genes & Development* are distributed under the Creative Commons Attribution-Non-Commercial 4.0 International License (CC-BY-NC). The CC-BY license permits commercial use, including reproduction, adaptation, and distribution of the article provided the original author and source are credited (as per <http://genesdev.cshlp.org/site/misc/terms.xhtml>).

Note: Figures 1-3, and S1 are new.

*8. Please upload the Tables as supplementary files individually.*

We have made this change to the arrangement of the tables and renamed them as Supplementary Files.

*9. Please replace the word "wormlife" with a more generic term as much as possible throughout the entire manuscript. Specific product names can be introduced or used infrequently if directly relevant but should not be used to the point where the protocol reads like an advertisement. You can certainly introduce the software but we ask the authors to reduce the instances to remove any bias.*

The number of mentions of the name of the software have been substantially reduced. We have only retained the word wormlife in a few instances (when referring to the software as a whole). Other instances where it has been retained are limited to cases where we are directly referring to a file name that is necessary to use the software.

*10. Please address specific comments marked in the manuscript as well.*

We have made modifications as appropriate in response to the comments in the manuscript and have replied to some comments with the review tools.



**TITLE:**

The Replica Set Method: A High-throughput Approach to Quantitatively Measure *Caenorhabditis elegans* Lifespan

**AUTHORS & AFFILIATIONS:**

Adam B. Cornwell<sup>1</sup>, Jesse R. Llop<sup>1</sup>, Peter Salzman<sup>2,3</sup>, Juilee Thakar<sup>4</sup>, and Andrew V. Samuelson<sup>1</sup>

<sup>1</sup> Department of Biomedical Genetics, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA

<sup>2</sup> Department of Biostatistics and Computational Biology, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA

<sup>3</sup> Non-Clinical Statistics. Bristol-Myers Squibb. 38 Jackson Rd. Devens, MA 01434

<sup>4</sup> Department of Microbiology and Immunology, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA

**Email Addresses of Co-Authors:**

Adam B. Cornwell (Adam\_Cornwell@URMC.Rochester.edu)

Jesse R. Llop (jesse.llop@gmail.com)

Peter Salzman (peter.salzmanwork@gmail.com)

Juilee Thakar (Juilee\_Thakar@URMC.Rochester.edu)

Andrew V. Samuelson (Andrew\_Samuelson@urmc.rochester.edu)

**Corresponding author:**

Andrew V. Samuelson (Andrew\_Samuelson@urmc.rochester.edu)

Phone: 585-273-2409

**KEYWORDS:**

Aging, lifespan, survival analysis, *C. elegans*, high-throughput, statistical analysis of quantitative phenotypes, software.

**SHORT ABSTRACT:**

Here we describe the Replica Set method, an approach to quantitatively measure *C. elegans* lifespan/survival and healthspan in a high-throughput and robust manner, thus allowing screening of many conditions without sacrificing data quality. This protocol details the strategy and provides a software tool for analysis of Replica Set data.

**LONG ABSTRACT:**

The Replica Set method is an approach to quantitatively measure lifespan or survival of *Caenorhabditis elegans* nematodes in a high-throughput manner, thus allowing a single investigator to screen more treatments or conditions over the same amount of time without loss of data quality. The method requires common equipment found in most laboratories working with *C. elegans* and is thus simple to adopt. The approach centers on assaying independent samples of a population at each observation point, rather than a single sample over time as with traditional longitudinal methods. Scoring entails adding liquid to the wells of a multi-well plate,

which stimulates *C. elegans* to move and facilitates quantifying changes in healthspan. Other major benefits of the Replica Set method include reduced exposure of agar surfaces to airborne contaminants (e.g. mold or fungus), minimal handling of animals, and robustness to sporadic mis-scoring (such as calling an animal as dead when it is still alive). To appropriately analyze and visualize the data from a Replica Set style experiment, a custom software tool was also developed. Current capabilities of the software include plotting of survival curves for both Replica Set and traditional (Kaplan-Meier) experiments, as well as statistical analysis for Replica Set. The protocols provided here describe the traditional experimental approach and the Replica Set method, as well as an overview of the corresponding data analysis.

## INTRODUCTION:

One of the most transformative technological advancements towards understanding the genetic basis of aging was the development of feeding-based RNAi in *C. elegans*<sup>1</sup>; prior to the experimental use of RNAi, many phenotypes of aging were not genetically tractable. Feeding-based RNAi is achieved through the production of dsRNA within *E. coli* that matches an endogenous *C. elegans* mRNA: IPTG induces bidirectional transcription across an insert of either *C. elegans* cDNA or a portion of an open reading frame within a plasmid<sup>2</sup>. When *C. elegans* feed upon intact *E. coli*, dsRNA produced by bacteria is transported from the lumen into intestinal cells via the SID-2 transmembrane protein<sup>3</sup>, and then distributed through the rest of the animal via SID-1<sup>4</sup>. Within each cell, exogenous dsRNA is processed by the Dicer complex into siRNA, which interact with a mature mRNA via complementary base pairing to create a new siRNA-mRNA duplex. This duplex is recognized by the RISC complex and cleaved, thereby degrading the endogenous mRNA<sup>5</sup>. Thus, by merely changing the plasmid insert, one can inactivate the function of nearly any gene within the *C. elegans* genome. This discovery led to the creation of several large feeding-based RNAi libraries- collections of transformed *E. coli* stocks that can be combined to achieve coverage of approximately 86% of known *C. elegans* genes<sup>6, 7</sup>.

Since the advancement of feeding-based RNAi, comprehensive screens in *C. elegans* have led to the discovery of more than 900 genes that alter lifespan when inactivated (as evidenced by the RNAi-phenotype associations curated in WormBase), which we refer to as gerogenes. A role for the majority of gerogenes in longevity control was discovered through feeding-based RNAi in just a few seminal reports (see **Figure 1A** and **Supplemental File 1** for details). In some cases, these gerogenes have been identified based on measuring the viability at a single or a few time points, which fails to provide a quantifiable measure of the change in lifespan with RNAi treatment. In other cases, these genes have been quantitatively assessed for changes in lifespan, as well as additional age-associated phenotypes. For instance, we previously identified 159 genes that were necessary for both normal and increased lifespan of animals with decreased insulin/IGF-1 signaling, and quantified changes in healthspan. Of these, 103 gene inactivations result in a progeric phenotype, as loss resulted in one or more signs of premature aging<sup>8</sup>.

While some gerogenes have been associated with 100 or more studies (e.g. *daf-16*, *daf-2*, *sir-2.1*), over 400 gerogenes have 10 or fewer citations (**Figure 1B**, and **Supplemental File 2**). Thus, while comprehensive feeding-based RNAi screens have discovered and cursorily characterized hundreds of putative gerogenes, how these genes function in longevity control, and the genetic

interrelationships between these gene products remain poorly studied. Full longitudinal analysis for age-associated phenotypes is a prerequisite for identifying genetic interactions between gerogenes (*e.g.* epistatic interactions, asynthetic interactions, *etc.*). Gaining deeper insight into the genetic interrelationships between gerogenes requires a high-throughput quantitative method, which also leverages the advantages of feeding-based RNAi.

The most common surrogate measure of aging is lifespan. The traditional approach for measuring *C. elegans* mortality tracks the deaths of individual animals over time within a small population sample. A relatively small number of animals are followed over time and periodically are gently prodded with either a platinum wire or eyelash, with movement as an indicator of viability (**Figure 2A**). This method has been widely used, as it provides straightforward, direct measurements of the average and the maximum lifespan. However, this traditional method is time consuming and relatively low-throughput, which limits the number of animals and conditions that can simultaneously be measured in a controlled manner. A recent simulation study found that many *C. elegans* lifespan studies do not assay a large enough number of animals to be able to reliably detect small changes between conditions<sup>9</sup>. Furthermore, this traditional method involves repeatedly handling the same cohort of animals over time, which in turn can introduce contamination, and can damage or kill increasingly fragile, aged animals.

We have developed an alternative “Replica Set” methodology for measuring *C. elegans* lifespan. To this end, a large population of age-synchronized, isogenic animals are divided into a number of small populations (or replicas). Enough replica samples are generated to cover each time point in the planned experiment. At each observation time point, one of the replicas is scored for the number of living, dead and censored animals, then animals within that replicate are discarded. Thus, over the expected lifespan of the population as a whole, a series of independent subpopulations are periodically sampled (**Figure 2B**). In using replica sets there is no repeated prodding of animals and no repeated exposure to potential environmental contamination. The viability observed at the one-time point is completely independent of every other observation, which minimizes handling and increases throughput by at least an order of magnitude. This has allowed us to quantitate changes in lifespan for hundreds of RNAi clones simultaneously<sup>8, 10</sup>.

Here we present detailed protocols for conducting *C. elegans* lifespan via both the Replica Set and traditional methods for scoring *C. elegans* longevity. We demonstrate that similar results are obtained between the methods. We have developed software to assist in the graphical analysis of lifespan data generated through either approach, which we freely provide under a GPL V3 license (See **Table of Materials**). “WormLife” is written in R<sup>11</sup>, and includes a graphical user interface (GUI) for plotting data, which has been tested in Mac OS and Linux. Lastly, we compare and contrast the limitations of each method and highlight other considerations when choosing between approaches to measure quantitative changes in *C. elegans* lifespan.

## PROTOCOL

### 1: Traditional Method for Scoring *C. elegans* Longevity

## 1.1. Preparation of reagents

1.1.1. Identify genes to be inactivated via feeding-based RNAi. Purchase transformed stocks of HT115 *E. coli*<sup>2</sup> containing the RNAi clone of interest. Alternatively, subclone the cDNA of the gene of interest into the multicloning site of the L4440 plasmid.

**Note:** HT115 is an RNase III-deficient *E. coli* strain with IPTG-inducible T7 polymerase activity, which is used to prevent degradation of dsRNA within the bacteria. For lifespan studies that do not use feeding-based RNAi, either HT115 or OP50 *E. coli* on standard NGM plates can be used.

1.1.2. Prepare 3-6 (or more) 6 cm RNAi plates per test condition (**Supplemental File 3** for recipe). Store RNAi plates at 4 °C before seeding with bacteria for up to several months.

1.1.3. Grow transformed *E. coli* overnight (16-20 h, 37 °C shaking incubator at 180 - 220 RPM).

**Note:** HT115 *E. coli* is grown in LB with ampicillin (50 µg/mL). Standard OP50 *E. coli* is not antibiotic resistant and is grown without ampicillin. Culture volume depends on the # of plates, but is typically between 8 and 100 mL of LB, depending on the experimental design.

1.1.3.1 Concentrate bacteria by centrifugation at 3,000 x g for 15-20 min in a benchtop centrifuge. Aspirate the supernatant, and re-suspend the pellet at 1/10th starting volume (*i.e.* 10x) in LB with ampicillin for HT115 (or without ampicillin for standard OP50).

1.1.3.2 Aliquot 200 µL of concentrated 10x bacteria to each 6 cm plate. Prepare 3-4 replicates per test condition, with 2 extra backup plates, to be used in case of contamination. When preparing plates, label them so the experimenter scoring the assay is blind to the experimental conditions, using a color code or similar coding scheme. Ensure that the code is recorded.

1.1.3.3 Allow open plates to dry in a clean environment such as a laminar flow bench until all liquid has been absorbed or allow covered plates to dry on the bench overnight. Monitor plates while drying to ensure that the agar is dry without over-drying.

**Note:** Over-drying the plates leads to cracking of the agar that will cause *C. elegans* to burrow into the agar. Wet the agar surfaces also promote burrowing.

1.1.4 Store dried plates within a worm box overnight (up to 24 h) at room temperature to allow induction of dsRNA production. After 1 day at RT, store plates at 4 °C for up to 2 weeks in a sealed zip-lock bag (to prevent plates from drying out). Before use, return plates to room temperature within the zip-lock bag to prevent condensation from introducing airborne fungal contaminants.

## 1.2. Synchronization of *C. elegans* with hypochlorite treatment

**Note:** See **Supplemental File 3** for M9 and hypochlorite solution recipes.

1.2.1 Collect gravid adult animals with M9. Use a plugged glass pipette to move to 2 x 15 mL tubes.

1.2.2 Spin tubes for 30" at ~2,000 RPM. Check for a pool of at nematodes at the bottom of the tube. Aspirate the supernatant. Wash two times with M9 solution, repeating spin and aspiration.

1.2.3 Re-suspend *C. elegans* in 4 mL of M9. Add 2 mL of hypochlorite solution. Immediately vortex for ~3 min, with periodic vigorous shaking. After 3 min, look for a cloud of eggs under a dissecting microscope. Vortex an additional 10-20 s if eggs have not been released after 3 min.

**Note:** Timing the hypochlorite treatment is essential. Eggs within the gravid adults are what survive treatment. After ~3 min the gravid adults break open and the eggs spill out. However, if eggs are in hypochlorite solution too long after release they will die. Conversely, if gravid adults are not left in hypochlorite solution long enough, no eggs will be released.

1.2.4 Quickly wash with M9 solution twice as in step 2.1.2.

1.2.5. Re-suspend *C. elegans* egg pellet in 3 mL M9 and transfer to a new 15 mL tube. Allow embryos to hatch overnight in 3 mL of M9 solution with rotation at 20 °C.

1.2.6 Calculate the density of L1 animals (or embryos) per  $\mu$ L by dropping 10  $\mu$ L of L1 solution 3x on a 6 cm plate and count the number of L1 animals to calculate the average number of L1s/ $\mu$ L.

**Note:** L1 animals will settle over time. Therefore, L1 solutions should be periodically mixed.

1.2.7 Seed 50 L1 animals per plate. Invert plates and seal with a rubber band. Place plates in a plastic worm box. Seal box in a large zip-lock bag. Move to a 20 °C incubator.

### 1.3. Preventing progeny production by the addition of 5-Fluoro-2'-deoxyuridine (FUdR)

1.3.1 Grow animals until L4 stage at 20 °C. Check to see whether synchronized animals have developed to L4 approximately 40 hours after seeding (step 2.1.7).

**Note:** *C. elegans* developmental time will vary at different temperatures<sup>12</sup> and growth rates of mutant animals for which rates have not been characterized must be empirically tested.

1.3.1.1 Add 160  $\mu$ L of 50x FUdR to each 6 cm plate with L4 animals.

**Note:** It is critical to add FUdR at the L4 stage. For convenience, make 1000x stocks of FUdR by dissolving 1 g FUdR into 10 mL ultrapure H<sub>2</sub>O. Filter-sterilize stock FUdR with a 0.2-micron filter and a 10 cc syringe. Aliquot ~1 mL of stock into sterile 1.5 mL tubes. Freeze and store at -20 °C.

1.3.2 Inspect plates for the presence of male *C. elegans*. Remove all males.

**Note:** Lifespan is typically measured for hermaphrodites and not males. Hermaphrodites that mate live shorter than unmated animals, even in the presence of FUdR<sup>13</sup>. Males are smaller and thinner than hermaphrodites and can be easily identified by a distinctive hooked tail<sup>14</sup>.

1.3.3 Put box back into the zip-lock bag. Return to 20 °C incubator.

#### 1.4. Scoring viability

1.4.1 Score viability daily by gently touching the animal on the head with a platinum wire or eyelash. Score animals that fail to move as dead and remove them from the plate (**Figure 2A**). Record the number observed dead for each condition for every observation time point.

**Note:** To reduce the risk of scoring bias, the experimenter must remain blind to experimental conditions and similarly must not reference the results from previous time points during scoring.

1.4.2 Censor animals that rupture, die from other obvious development defects, or crawl up on the side of the dish: remove these animals and record the number at each observed time point for consideration in the statistical analysis. Additionally, if males are found, remove them and record the number observed.

1.4.3 Repeat from step 1.4.1 daily until no animals remain alive.

**Note:** Should the lawn of *E. coli* diminish significantly or fungus begins to grow upon the plate, transfer all remaining animals to a fresh plate with the appropriate RNAi and FUdR.

#### 1.5. Data analysis- plotting and statistics

1.5.1 Input or open recorded observation data in software supporting survival analysis with the non-parametric Kaplan-Meier estimator<sup>15</sup> and log-rank test<sup>16</sup> (See **Supplemental File 3**). Be sure to include censored animals. Do not include males that were observed, if any.

**Note:** Data formats may vary between software, but a common format is to record each individual animal observed on a separate line. The experimental timepoint at which an animal was observed as dead is the “event” time. If censored, the “event” time is the timepoint at which the animal was censored. There is usually a field or checkbox to indicate censored observations.

1.5.2 Plot Kaplan-Meier survival curves. Select fewer than six conditions for a single plot if many conditions were assayed to improve readability.

1.5.2.1 Check for data issues that are visually apparent- missing observations, unexpected control results, etc.- and address these before statistical analysis.

1.5.3 Use the log-rank test function in your software to perform pairwise statistical comparisons. Ensure that any available options for treatment of censored results are set appropriately for right-censored data.

## 2: Replica Set Method for scoring *C. elegans* longevity

**Note:** While the traditional method requires 3-6 plates per condition (see 1.1.2. above), the Replica Set method requires many more (see step 2.2.2 below). The traditional method follows animals on the same plate throughout an experiment (**Figure 2A**). In contrast, with Replica Set animals are only scored once: many identical replicates are set up at the beginning of the experiment so that one replicate is scored at each time point (per trial) (**Figure 2B**).

### 2.1. Library setup.

**Note:** Additional detail on handling RNAi clones is covered here, as the Replica Set protocol is amenable to the simultaneous scoring of many RNAi clones, and can be scaled to well over 100 clones at a time. Collections of RNAi clones are preserved as glycerol stocks maintained in a 96-well format plate. Replica Set experiments use 24-well plates. Each well is a different test condition, which may correspond to a collection of RNAi clones, different chemical treatments, animal strains, and so forth.

2.1.1 Assemble the layout of the sublibrary for collections of RNAi clones, such that the following conditions are met:

2.1.1.1 Ensure that within a 96-well collection, well A1 is an empty vector negative control.

2.1.1.2 Insert an additional empty vector control randomly within every 24 wells.

2.1.1.3 Split the 96-well plate into blocks of 24 wells, such that each 24-well plate has at one randomly inserted negative control (**Figure 2C**).

2.1.1.4 Insert a positive control randomly within every group of 24-wells (**Figure 2C**).

**Note:** The positive control is dependent on the experimental question. For example, when looking at a collection of RNAi clones that increase lifespan, *daf-2(RNAi)* is frequently included. Conversely, when looking at shortened lifespan, *daf-16(RNAi)* is frequently used.

## 2.2. Preparation of replica sets

**Note:** The number of replicates needed is equal to the minimum number of time points (**Figure 2B**). One must know *a posteriori* how long to measure lifespan prior to the start of the experiment, as well as scoring frequency (*e.g.* a replica set experiment running 40 days with every other day scoring requires preparing a minimum of 20 replica sets for each condition at the start of the experiment). It is advisable to make ~5 extra backup sets (see 2.2.2 and 2.2.2.3 below).



2.2.1 To create a fresh stamp of the RNAi sublibrary, inoculate 200  $\mu$ L LB+Amp per well in a 96-well format (600  $\mu$ L plates) using a 96-pin plate replicator by the following steps:

2.2.1.1 Sterilize 96 pin plate replicator by sequentially immersing the pins in 50% bleach, ultrapure H<sub>2</sub>O, and ethanol. Keep the pins immersed for at least 30 s for the bleach and ethanol steps. After immersion in ethanol, flame the tips briefly. Repeat.

**Note:** Be sure to rinse off all bleach, and do not leave the pins exposed to bleach for extended periods, as bleach can corrode the stainless-steel pins.

2.2.1.2 Carefully remove adhesive foil cover from frozen 96-well glycerol stock library plate and gently but firmly grind tips of the sterilized plate replicator into the wells of the still frozen glycerol stocks. Inoculate 200  $\mu$ L LB+Amp cultures and seal the inoculated plate with a permeable membrane. Allow cultures to grow overnight on the benchtop.

2.2.1.3 Sterilize the plate replicator as in step 2.1.1, carefully remove the seal from the liquid culture plate after overnight growth and immerse tips of the replicator pins. Apply the tips with even pressure to a rectangular LB amp+tet agar plate, and transfer bacteria from the pins to the plate gently with a small circular motion, ensuring that adequate space is left between adjacent spots. Allow colonies to grow overnight on the agar plate at 37 °C. See **Supplemental File 3** for preparation of LB + Amp/Tet plates.

2.2.1.4 Prior to use, store agar plate at 4 °C inverted (lid side down), wrapped in paraffin film.

**Note:** Storing colonies lid side up will allow condensation to cross-contaminate RNAi clones! Colonies of *E. coli* can be stored for 2-8 weeks at 4 °C, depending on particular RNAi clones, as RNAi clones retain efficacy in inducing dsRNA after IPTG induction for variable lengths of time. For small collections of RNAi clones, RNAi efficiency should be empirically determined by RT-qPCR to confirm knockdown.

2.2.2 Calculate the minimum number of 24-well plates necessary for one trial of the experiment: (# plates per replica set) x (expected # time points). Ensure that a few extra replica sets are included for handling issues such as contamination (**Figure 2B**).

Note: The total number of RNAi clones determine the number of 24-well plates to make one set of replicas for each time point (**Figure 2C**).

2.2.2.1 Prepare 24-well plates, as step 1.1.2 (**Supplemental File 3** for recipe). Label plates when preparing them so the experimenter scoring the assay will be blind to the experimental conditions, using a color code or similar coding scheme.



2.2.2.2 Inoculate one set of 1.5 mL LB+Amp cultures for every 10 replicas (see 2.2.2). Inoculate cultures in 96 well deep-well plates using the plate replicator (as in 2.1.3) and bacterial colonies from 2.1.4 (**Figure 2C, left**). Seal with breathable membrane, grow 20 h ( 37 °C) with shaking.

2.2.2.3 Seed 120 µL of an overnight culture to each plate using a 6-well multichannel pipette with adjustable tip spacing (**Figure 2C, right**). Dry plates uncovered in a laminar flow hood until all liquid has been absorbed. Do not over-dry. Store plates overnight at room temperature.

## 2.3. Synchronization of *C. elegans* using hypochlorite treatment

2.3.1 Calculate the minimum number of animals needed for the experiment: minimum # of L1s needed = (15-20 animals/well)(24 wells/plate)(X plates/replica set)(Y replica sets).

**Note:** The Replica Set method requires more animals than the traditional method. One 10 cm plate full of gravid worms can provide 20,000-50,000 L1 animals depending on the density of gravid adults. Similarly, 20 6 cm plates yield around ~30,000 L1 animals. Plan to prepare an egg preparation that doubles the minimum number of animals needed. If the population in preparation has starved, re-feed or chunk to a new plate and allow at least three generations on food before proceeding<sup>17, 18</sup>. Be sure to freeze back leftover L1s.

2.3.2 Follow steps 1.2 to 1.2.6 as in the traditional method to obtain synchronized L1 animals. Seed 15-20 L1 animals into each well using a 6-well adjustable-spacing pipette and reagent reservoir, similar to 1.2.7. Periodically mix L1 solution prevent settling of animals.

## 2.4 Prevention of progeny production by the addition of 5-Fluoro-2'-deoxyuridine (FUdR)

2.4.1 Follow step 1.3.1. Prepare sterile 50x FUdR stock (see step 1.3.1.1).

2.4.2 When animals reach L4, add 25 µL of 50x FUdR to each well of a 24-well plate using a 6-channel adjustable-spacing pipette.

## 2.5. Score viability

2.5.1. Remove one set of replicate plates and flood wells with the M9 solution, record total animals per well, and then gently touch non-moving animals on the head with a worm pick (**Figure 2B**). Animals failing to move are scored as dead. Discard scored plates. Record viability daily.

**Note:** Animals that rupture, show gross morphological defects, failed to develop, or crawled up on the side of the well are to be censored by excluding them from both the dead and total values.

2.5.1.1 Record the number of animals that are censored within each well at each time point separately from the other values.

2.5.1.2 **Do not score wells that do not have food or are contaminated** (e.g. fungus or slime); such wells are considered censored. Also, censor a well if all of the animals display morphological or developmental defects. Record the censoring event for this RNAi clone/well at this time point.

2.5.1.3 **After scoring a replicate plate, discard it.** Continue scoring a new replicate set each day until all animals across all wells are dead. To reduce the risk of scoring bias, the experimenter must remain blind to experimental conditions and similarly must not reference the results from previous time points during scoring.

2.5.1.4 If all animals within a well were dead at a given time point, then after that day's scoring, examine whether all animals have been scored as dead for two consecutive time points for a given well. If so, scoring viability is no longer needed for that well in subsequent time points.

2.5.1.5 Conduct additional independent experiment trials. Track the results of successive trials separately from those in previous trials, with the trial number noted.

### 3. Graph data

**Note:** With the Replica Set method a curve fit is applied to approximate the mean and maximum lifespan. The parameters for assessing *C. elegans* mortality fit a logit curve<sup>19</sup>. As most survival tools do not support logit curve fitting, a new program was developed for plotting logit curves (for Replica Set); Kaplan-Meier curves (for the traditional method) are also supported.

3.1. Get started with the software. Download the release zip file for the current version (See Materials). Extract the zip file to a folder. See the **readme** file in the extracted folder for additional installation instructions.

3.1. Start the plotting interface. Find the location of the **code** directory in the folder extracted from the zip file (e.g. `"/Users/UserName/Desktop/WormLife/code"`).

3.1.1 Enter the following commands in the R console, substituting for the folder path just identified. Press enter or return after each entered line: 1) `setwd("/Users/UserName/Desktop/WormLife/code")`, 2) `source("plotGUI.R")`, 3) `openMain()`.

3.1.2 Allow time for the interface to load in a new window, bringing up the default screen as shown in **Figure 3A**. Let the R run in the background.

3.2 Format data as comma-separated value (CSV) or tab-separated value (TSV) files. Specify columns and names, dependent on the type of analysis. See **Supplemental File 4** (Replica Set) and **Supplemental File 5** (traditional/Kaplan-Meier) for pre-formatted example data.

**Note:** Data must be specified in a **long** format, i.e. one row per strain/treatment per time point per trial. CSV files are recommended for best compatibility between platforms.

3.2.1 Remove rows corresponding to observations that were skipped or censored. Check for the absence of missing or non-numeric values, as it may result in an error when the data is imported.

3.2.2 For traditional Kaplan-Meier style analysis, do not pool data from independent trials- plot them separately. For Replica Set analysis, pool data from multiple trials, and then investigate using the **TrialView** functionality (see 6.3.3.4).

### 3.3 Using the plotting interface

3.3.1 Load a data file (**import** under the **File** menu) using the dialog box. To open **.csv** files, change the file type in the drop down to **.csv** (the default is **“.txt/.tsv”**), navigate to the folder with the data file. Here the file is the Replica Set example data (**Supplemental File 4**).

**Note:** Importing a file when a dataset is already open will replace the current dataset.

3.3.2 Select a file to import to start the import wizard, which walks through identifying the columns of the selected file (**Figure S1A** for Replica Set). If the input data corresponds to a replica-set experiment, choose **Logit** for study type.

**Note:** The import workflow is different between Replica Set (**Figure S1A**) and traditional (Kaplan-Meier) (**Figure S1B**).

3.3.3 **Plot data.** Select **“Add Line”** to begin plotting data. (A line corresponds to one set of conditions. There are features to help with experiments where many conditions were tested).

3.3.3.1 Plot the control conditions- in the case of the example data N2 (WT) with L4440 (empty vector) RNAi are appropriate. Select **Add Line** under the **Graphs** menu to initiate the Add Line wizard: select the condition to plot and the graphical parameters for representing the line.

3.3.3.1.1 To add a curve for a different condition manually, repeat the steps in 3.3.3.1

3.3.3.1.2 To change color or plot symbol for a line, select **Modify Line** under the **Graph menu**.

3.3.3.1.3 To remove a line without clearing all lines, select **Delete Line** under the **Graph menu**.

3.3.3.1.4 To clear all lines in the current plot, select **Clear Line** under the **Graph menu**.

3.3.3.1.5 To override the automatically selected maximum x-axis (time) value, use **Set X scale** under the **Graph menu**.

**Note:** The y-axis (surviving fraction) always displays 100% (top) to 0% (bottom) in increments of 20%. The x-axis is always displayed in increments of 5. Axis labels are not plotted to enable flexibility in labeling after saving plot images.

3.3.3.2 To save JPEG-format images of the currently displayed plot, use the **Save Plot** option in the **File menu**; only the current plot is saved.

3.3.3.3 For creating individual plots for many different conditions in one experiment, the software allows defining and plotting a **series**.

**Note:** The implementation of the series concept improves efficiency when working with large experiments.

3.3.3.3.1 If starting with a blank plot workspace, add lines corresponding to control conditions that are to be consistent across all plots in the series (see 3.3.3.1).

3.3.3.3.2 Define the series with “**Define Series**” in the Graphs menu. Select a condition corresponding to the line to display first in the series; only one can be selected. Choose graphical parameters (line color and plot symbol) for the line, as in 3.3.3.1.

3.3.3.3.3 Review the plots for the different test conditions. Switch the display of the “**series line**” between conditions using the left/right arrow buttons found on the sides of the main plot window as well as in the top menu bar (**Figure 3A-C**).

**Note:** If the selected series line is the same condition as one of the previously added control/reference lines, the new line may appear overlaid.

3.3.3.3.4 Define the series to make certain other functions available (Save Series Plots and Trialview- see 3.3.3.4 for the latter). After defining a series, use the “**Save Series Plots**” option from the “File” menu to save individual plot image files for each plot in the series in a new folder.

**3.3.3.4 Trialview- visualizing results from independent trials of a Replica Set experiment.** If multiple trials were run for one or more of the sample groups, plot the data from the individual trials and the pooled data from all trials separately to evaluate the consistency between independent trials (See **Figure 3D**).

3.3.3.4.1 Set up a series as described in 3.3.3.3. The different trials will be plotted for each of the “varying” sample groups in a different image over the respective trials for the specified reference/control samples.

3.3.3.4.2 To save the TrialView images, go to **Print TrialViews** in the Data menu; a JPEG image will be output for each plot in the series.

**Note:** The example results in **Figure 3D** is for a case with two trials.

**3.3.4 Median lifespan summary table for Replica Set data.** Visually inspect curves to ensure reasonable fit of the data, then select the **Summary Table** option in the Data menu to save a table of median lifespan values (time at 50% survival on logit curve) for each sample type.

### 3.4 Statistical evaluation of data generated via the Replica Set method

3.4.1 For statistical analysis between two groups from a Replica Set experiment, modify and run an R script, provided in the release zip file (see “WormLife statistical analysis template script.R”).

**Note:** Proficiency in R is not required to run the script. Additional documentation is in comments in the file. The script is ready for analysis of the example Replica Set data. User-generated data in the appropriate format (see **Supplemental File 4**) can also be analyzed.

3.4.1.1 Open the script file in R (R GUI or RStudio).

**Note:** This will display the script without running it.

3.4.1.2 Modify the locations of necessary files to match the location on your computer.

**Note:** These file paths must be **fully qualified** (i.e. should include the complete file location, including folders).

3.4.1.2.1 Modify the paths (file/folder locations) for **wlDir** (location of the directory), **dataFile** (the Replica Set data file to analyze), **compFile** (specification of comparisons to run, if applicable), and **outputPath** (location where result files will be written to).

3.4.1.3 Set the column names in the **Specify columns in data file** section if column names in the file to be analyzed are different from the example file. Specify a column for each parameter. If a study has multiple strains, but no RNAi (or other treatment) include a column in the data file with blank entries or the same for all rows (e.g. “no\_treatment”, etc.).

3.4.1.4 Set the **compFile** parameter. If the **compFile** parameter is set to NA, then all possible pairwise comparisons of groups will be run.

**Note:** A group is defined by the combination of strain/genotype and treatment, which are concatenated and displayed as “strain\_treatment”. For larger studies with many groups, a CSV file specifying comparisons can be provided. See the example file “comps\_rsm\_example.csv”.

3.4.1.5 Set the number of iterations for Monte Carlo resampling (**k.resamp**, the default is 1000).

**Note:** P-values of 0 may be returned when too few iterations are performed; in such cases it is appropriate to report “p < 0.01” (if k.resamp = 100), or “p < 0.001” (if k.resamp = 1000), etc.

3.4.1.6 Run the script: **source** button in RStudio (top right of the edit window) or **source document** in the **edit** menu in the R GUI. (Execution may take some time.)

3.4.1.7 When the R **busy** indicator is no longer displayed, open the output directory- there will be a table with results of each comparison (median survival, p-values, % median lifespan change).

#### **REPRESENTATIVE RESULTS:**

In the development of any new methodology, it is imperative that the new method recapitulates accepted results from previous approaches and meets the standard within a field. We have previously shown empirically that the Replica Set and traditional methods for assaying *C. elegans* lifespan produce similar results<sup>20</sup>. Wild-type *C. elegans* (N2) maintained at 20 °C typically live between 20 and 25 days, which we observed with both the traditional (**Figure 4A**, black line) and Replica Set approach (**Figure 4B**, black). Thus, both methods reasonably approximate wild-type lifespan. It is also essential that a new method has the resolution to accurately quantify changes between test conditions and the statistical power to detect significant changes. In our previous study, we discovered that the Myc family of transcription factors are determinants of *C. elegans* longevity. *mml-1* and *mxl-2* encode the *C. elegans* homologs of mammalian Mondo A/Carbohydrate Response element binding protein (ChREBP) and Mlx, respectively. In both *C. elegans* and mammals, these Myc-family members heterodimerize to regulate transcription. We found that loss of either *mml-1* or *mxl-2* significantly decreases normal lifespan, as measured by either a traditional lifespan assay or by Replica Set (**Figure 4A-B**, yellow and maroon). In contrast to the MML-1::MXL-2 complex, we found that loss of either *mdl-1* (homologous to mammalian Mad) or *mxl-1* (Max) significantly increased *C. elegans* lifespan as measured by either methodology (**Figure 4** purple and blue, respectively, in both panels).

A serious limitation to the traditional approach for measuring longevity is throughput. Both methods rely on movement to call whether an animal is alive or dead, which becomes increasingly difficult to assess. Young animals will move throughout a plate in the absence of stimuli and are thus easy to score. Aging *C. elegans* become increasingly sedentary but will respond to a light touch to the head by a reversal movement on a plate. However, as animals become older the ability to move backward diminishes and becomes increasingly uncoordinated. Ultimately animals become paralyzed, a phenotype strongly resembling sarcopenia, and when scoring via the traditional method viability can only be determined by observing subtle twitch at the extreme anterior tip of the animal. In contrast, when scoring viability via the Replica Set method, the liquid is added to the well, which acts as a stimulus that generates a thrashing response that can be quantified as a readout of healthspan<sup>8</sup>. Movement in the liquid is easier to observe for even older animals: chronologically age-matched decrepit animals produce subtle head movements on dry plates but a more pronounced (albeit slow) body bend in liquid. Finally, when scoring Replica Set, the whole well is within the field of view (approximately 1.1 cm in diameter) and all animals are in suspension- allowing observation of all animals simultaneously. In contrast, when scoring a 6 cm plate via the traditional method, one must scan across the entire plate -searching through the bacterial lawn and along the edges for animals. The net consequence of these differences is that the throughput when using the Replica Set method is at least an order of magnitude greater than the traditional approach, which makes it possible to simultaneously quantify changes in lifespan across more than 100 conditions in a single experiment with one investigator. For example, from a genome-wide feeding-based RNAi screen we previously identified 159 genes that were necessary for the increased lifespan conferred by

decreased *daf-2*/insulin-like signaling<sup>8</sup>. In that analysis, we quantified the changes in lifespan in wild-type, a long-lived *daf-2(e1370)* mutant, and short-lived *daf-2(e1370);daf-16(mgDf47)* double mutant animals (**Figure 5A**), which allowed us to decipher the genetic relationships between insulin-like signaling and over 100 progeric gene inactivations. Further, we assessed how these progeric gene inactivations altered healthspan (at the time called “activespan”) by observing the decline in *C. elegans* thrashing across replicates over time (**Figure 5B**).

#### FIGURE AND SUPPLEMENTAL FILE LEGENDS:

**Figure 1. The advent of feeding based RNAi lead to an era of gene discovery in aging research, yet most gerogenes remain poorly studied. (A).** Many gerogenes were initially discovered from large scale functional genomic screens. Of the more than 900 *C. elegans* gerogenes discovered to date, many were identified using feeding-based RNAi, highlighting the value of functional genomic approaches in gene discovery. The graph shows the number of gerogenes discovered per manuscript using RNAi, based on phenotype annotation (See **Table of Materials**) for phenotype ontology terms extended life span, shortened life span, and life span variant. See **Supplemental File 1** for the full list of studies that discovered gerogenes. **(B).** Most gerogenes remain poorly studied. In contrast to well-studied gerogenes like *daf-16*/FOXO (arrow), which has more than 800 references, the majority of gerogenes have fewer than 10 references (general reference- not necessarily focused on lifespan). Reliable high-throughput methods will be essential to derive deeper insight into the genetic inter-relationships between gerogenes. The graph is based on mappings between publications in PubMed and the *C. elegans* gerogenes discovered from RNAi phenotypes. See **Supplemental File 2** for the full list of gerogenes and number of studies associated with each.

**Figure 2. The Traditional and the Replica Set Method for scoring *C.elegans* lifespan (A).** The Traditional Method for scoring *C. elegans* lifespan. Several small synchronized populations of isogenic animals per condition are followed over time. The same population of animals is followed throughout the study course. Viability is assessed by movement, which may be stimulated by gentle prodding. Animals that fail to move are scored as dead and are removed (aspiration shown) until no viable animals remain. **(B).** The Replica Set Method for scoring *C. elegans* lifespan. A large population of age-synchronized isogenic animals are distributed across a number of identical replicate plates. At each time point, a single replicate is scored: a mild buffered solution (M9) is added, which stimulates movement. Animals that fail to move spontaneously after flooding wells are also assessed via touch stimulus. The scoring duration for the experiment is determined prior to the start. Each animal is scored only once and longevity for the larger population is derived from many independent observations. **(C).** The Replica Set approach is a high throughput method to quantitatively measure *C. elegans* lifespan. 100 or more independent RNAi clones can be tracked simultaneously. HT115 *E. coli* expressing dsRNA for a given RNAi clone is shown. Practically, every 24 samples from the 96-well plate are divided into a single 24-well plate. Each resulting 24-well plate has a negative (i.e. empty vector, red well) and positive control (green well) randomly distributed within a collection of RNAi clones (yellow wells). Typically, the first well (A1) in a collection contains an empty vector.

**Figure 3. The graphical user interface (GUI).** (A). The main plot window interface showing the default welcome screen. This is what is displayed upon opening the software. Differences in appearance between platforms should be minimal due to use of a platform-independent windowing toolkit. (B). Overview of menu options, for the drop-down menus available from the main plot window. (C). Example plot output for both Replica Set style (left) and traditional Kaplan-Meier style (right) data. The data displayed was collected in independent experiments. Exported plots do not include pre-plotted axis labels, for maximum flexibility in adding such labels. To facilitate this, the axes are always divided into increments of 20% for the Y-axis, and increments of 5 for the X-axis. In this example, axis and line labels (strain/treatment) were added to the saved plots, using a very simple and common image editing tool. (D). An example of output from the “TrialView” functionality, allowing for the visual comparison between results of independent trials for Replica Set style datasets. This plot shows the result between two different trials and the corresponding pooled results for *daf-2* EV(RNAi) (blue, closed circles), N2 EV (RNAi) (black, closed circles), and *daf-2* with *daf-16* (RNAi) (red, open diamonds). TrialView allows for quickly checking for trial-specific data issues that might affect the quality of the fit of the pooled dataset.

**Figure 4. The Traditional and Replica Set methods produce similar results.** Loss of either component of the MDL-1(Mad)::MXL-1(Max) heterodimer increases lifespan. In contrast, loss of either component of the MML-1 (Mondo/ChREBP)::MXL-2(Mlx) decreases lifespan This figure is reprinted from<sup>20</sup> with permission via a Creative Commons Attribution (CC BY) license (See Materials). (A). Kaplan-Meier results with the traditional method. (B). Logit curve fit using the Replica Set method.

**Figure 5. The Replica Set method can decipher genetic interactions based on changes in lifespan (A) and alterations in healthspan (B) for over 100 RNAi clones simultaneously** This figure is reprinted from<sup>8</sup> with permission under the Creative Commons Attribution-Non-Commercial 4.0 International License (CC-BY-NC) (See Materials). (A). Genetic lifespan analysis of progeric gene inactivations in the context of decreased insulin-like signaling (ILS) (*daf-2*, x-axis) and in the absence of *daf-16*/FoxO (Y-axis), a central transcriptional effector of ILS<sup>21</sup>. Gene inactivations with similar functions as *daf-16* do not further shorten lifespan in the absence of *daf-16* (black dots). Gene inactivations with functions completely independent from *daf-16* shorten both genetic backgrounds similarly (grey). Gene inactivations where the negative effect on lifespan in *daf-2* > *daf-2;daf-16*, suggests function in parallel (white). (B). Changes in thrashing rates over time can derive the average healthspan for many genetic perturbations (x-axis) while assessing changes in lifespan (y-axis).

**Figure S1. Workflows in WormLife.** Illustration of the steps of some guided workflows (sometimes termed “wizards”). In each of these cases, after the last step in the workflow, the focus is returned back to the main plot window. (A). The data import workflow for Replica Set style datasets (B). The data import workflow for traditional Kaplan Meier style datasets. (C). The workflow for adding lines to a plot for Replica Set style datasets. (D). The workflow for adding lines to a plot for traditional Kaplan Meier style datasets.



**Supplemental File 1. Studies that have identified gerogenes.** The advent of feeding-based RNAi led to an era of gene discovery for phenotypes that were not tractable by forward genetics, including aging. Listed, in the order of the number of gerogenes discovered, are independent studies that identified genes whose activity altered lifespan. Note that the study that identified the most gerogenes utilized the replicate set method<sup>8</sup>. The nature of how gene inactivations altered lifespan is also indicated: longevity and progeric genes are those that increased or decreased lifespan when inactivated, respectively. “Life span variant” refers to cases where directionality of change (i.e. increased or decreased lifespan) was not specified or has not been curated. Data from WormBase WS262 (January 2018) (See Materials), with the addition of RNAi-treatment lifespan results from <sup>10</sup>, which are not yet included in the curated collection of WormBase RNAi phenotypes.

**Supplemental File 2. The number of studies associated with each gerogene.** Most gerogenes are poorly studied. While some genes, like *daf-16*/FoxO, have been the subject of much research attention, more than 400 gerogenes have fewer than 10 associated publications. Data from WormBase WS262 (January 2018), with the addition of RNAi-treatment lifespan results from <sup>10</sup> which are not yet included in the curated collection of WormBase RNAi phenotypes.

**Supplemental File 3. Preparation of common reagents for *C. elegans* experiments. (A).** Recipe for standard NGM and RNAi plates. **(B).** Recipe for M9 buffer and hypochlorite solution. **(C).** Preparation of LB +Amp/Tet plates.

**Supplemental File 4. Replica Set example data.** An example dataset from a Replica Set lifespan experiment. This dataset is already formatted to be suitable for import/analysis. Includes two trials per condition (combination of strain/genotype and RNAi).

**Supplemental File 5. Traditional longitudinal example data.** An example dataset from a traditional longitudinal lifespan experiment, with right-censoring, formatted for ready import/analysis using Kaplan-Meier survival plot functionality.

## **DISCUSSION:**

Both the traditional and replica set methods require the synchronization of chronologically aged animals. We include a method that synchronizes animals using hypochlorite treatment of gravid adults, where only fertilized eggs with the gravid adult survive treatment. These embryos hatch in liquid suspension and developmentally arrest at the first larval stage (L1). After seeding L1 animals onto food (e.g. *E. coli* expressing dsRNA to a gene of interest), animals resume development. Synchronizing L1 animals by hypochlorite treatment of gravid adults has the advantage that the leftover unseeded L1 animals can be frozen and stored indefinitely in liquid nitrogen or a -80 °C freezer. In this way, a sample of each strain at the time of the experimental setup is preserved, creating a valuable resource for future studies and improving reproducibility. However, while hypochlorite treatment of gravid adult animals is a common way to obtain synchronized animals for aging research<sup>22</sup>, the L1 arrest is a starvation response. Thus, some laboratories prefer either to allow hatching to occur on plates, or to forgo hypochlorite treatment altogether and allow a few gravid adults to lay eggs for several hours (i.e. an egg lay). In the latter

case, parents are removed and the progeny lifespan is followed. To the best of our knowledge, no obvious differences in lifespan have been reported between animals that were synchronized in M9, hatched on plates, or progeny from an egg lay. However, given that changes in nutrient availability are closely linked to changes in lifespan, there is precedence that specific genetic backgrounds could produce different outcomes between these synchronization approaches. A more careful analysis is required to resolve this theoretical concern.

Regardless of the method used to synchronize the starting population, steps must be taken to either prevent progeny production or to separate the synchronized starting population from future progeny. In our protocol, we outline how to use FUdR to prevent progeny production, as separating animals is not a viable option for the replica set method. It is also possible to prevent progeny production genetically through the use of a feminized genetic background (*e.g. fer-15(b26);fem-1(hc17)*, which is a temperature-dependent sterile strain<sup>23</sup>). However, neither is without shortcomings: the use of genetic backgrounds can complicate subsequent analysis, and in some genetic backgrounds FUdR can alter longevity<sup>24–26</sup>.

As an alternative to preventing progeny production through chemical or genetic means, adult animals can be periodically moved to fresh RNAi plates to isolate them from their progeny. This simplifies background considerations at the expense of throughput. Periodically moving animals to fresh food has the additional advantages of preventing possible starvation and renewing exposure to dsRNA. However, some genetic interactions that influence lifespan were only discovered when progeny production was inhibited: early analysis of the TGF $\beta$  pathway for a lifespan phenotype erroneously concluded that decreased TGF $\beta$  signaling influenced *C. elegans* dauer formation but not aging<sup>27, 28</sup>. However, a follow up study that used FUdR revealed that decreased TGF $\beta$  signaling increased longevity through insulin signaling<sup>29</sup>. Why did earlier studies fail to see increased lifespan in TGF $\beta$  mutant animals? TGF $\beta$  pathway mutations produce a slight egg laying defect (*egl*) and extend reproductive longevity, which causes internal hatching of progeny later in life that kills the parent. It is likely that the long-lived TGF $\beta$  mutant animals appeared to have a normal lifespan because of the *egl* phenotype killed the animals around the time when wild-type animals normally die. This might be relevant to other genetic pathways linked to DR, as starved wild-type animals also manifest an *egl* phenotype, perhaps as an adaptive survival advantage to progeny under conditions of low food. This highlights the underlying complexity in adaptive responses animals undergo under stress conditions, and the need for careful analysis and consideration when designing lifespan experiments.

In designing and conducting lifespan experiments by either method it is critical to avoid bias. Experiments must be conducted in a double-blind manner: how samples were previously scored at previous time points and the identity of a test condition must be unknown to the experimenter. Furthermore, it is always necessary to include both positive and negative controls; in the case of the replica set method, these are randomly inserted into a 24-well plate. *E. coli* expressing a plasmid that does not contain an insert with the sequence corresponding to the *C. elegans* genome is the empty vector negative control (*i.e.* “L4440”- See Materials). Positive controls are dependent on the specific nature of an experiment. For instance, *daf-2* encodes the *C. elegans* insulin/IGF-1 receptor, and *daf-2* inactivation via feeding-based RNAi robustly

increases lifespan at least two-fold in wild-type animals<sup>27</sup>. Thus *daf-2(RNAi)* might serve as a positive control when looking for gene inactivations that increase lifespan. Conversely, *daf-16* encodes the FOXO transcription factor orthologue<sup>30</sup>. DAF-16 is an essential component of many longevity paradigms and wild-type animals (N2) treated with *daf-16(RNAi)* are short lived and show signs of progeria<sup>31</sup>.

The primary advantages of the traditional longitudinal lifespan approach are that it is very well established, and experiments are easy to set up. Relatively few animals are needed on just a few plates for each test condition. Thus, strains that grow poorly or require balancers to propagate can be easily tested. The traditional approach is highly adaptable and can be used with any one of the available approaches for handling progeny production, including treatment with FUdR, crossing into a feminized genetic background, or periodically moving adult animals to new plates during the egg-laying period. While moving animals greatly reduces throughput, working with a mutant background is never ideal, and although FUdR does not alter wild-type lifespan<sup>32–34</sup>, it can affect lifespan and age related phenotypes in some genetic backgrounds<sup>35, 25, 24, 26</sup>. Note that the presence of males, even with the use of FUdR, will significantly shorten hermaphrodite lifespan<sup>13</sup>, thus a plate that contained males after the hermaphrodites reached L4 is unusable. Likewise, analysis through the Kaplan-Meier estimator and associated curves, and the log-rank test, is well established for mortality data. However, there are several disadvantages to the traditional lifespan analysis. Repeated handling of plates (i.e. exposing the plates to air) facilitates the introduction of airborne fungal contamination. Additionally, repeated poking can damage or kill animals, especially as the population advances in age and become fragile. Older animals become largely paralyzed and mired in *E. coli*, while *E. coli* becomes an opportunistic pathogen (colonizing the lumen and packing the pharynx)<sup>36</sup>. Very old living animals can only be identified by subtle head movements. Thus, it is easy to classify a decrepit live animal as dead. Lastly, the traditional approach is limited by throughput.

The Replica Set method is high throughput and quantitative. However, the disadvantage of this method is a larger investment of time and resources in the initial set up. A moderately large experiment to examine 100 RNAi clones over 20 time points requires 30,000 L1 animals (where approximately 15 animals are examined per RNAi clone per time point), which while easy for most strains, can be problematic in some cases. For instance, without a large-particle sorter (“worm sorter”) strains that must be maintained with balancers or transgenic lines carrying a poorly transmitted extra-chromosomal array cannot be easily examined by this method. A second disadvantage is that progeny production must be inhibited, which requires the use of FUdR or a feminized genetic background. Finally, one must know the length of time the assay will run, as one must prepare a replica set for each time point at the beginning of the experiment. However, the advantages of this method are numerous. Foremost, scoring viability is much faster and one can easily follow animals over 100 test conditions simultaneously (i.e. RNAi clones). Since a replica set is only scored once then discarded, there is no repeated handling of plates or poking of animals, which minimizes the likelihood of fungal contamination and eliminates mortality caused by the occasional rough prodding with a worm pick. Furthermore, the addition of liquid to the well greatly facilitates scoring. Freeing old animals from the plate and surrounding bacteria assists in allowing subtle head movements to be more easily scored. Addition of liquid also

provides the opportunity to measure thrashing rates as a measure of fitness (*e.g.* healthspan<sup>8, 37</sup>).

Aging is a complex phenomenon involving multiple causal mechanisms which require use of systems biological approaches to unravel. These approaches often incorporate data-driven modeling, using large volumes of genomic/transcriptomic data, and require complementary robust and high-throughput methods to measure lifespan and healthspan. The high-throughput Replica Set method will allow comparison of many RNAi clones longitudinally, while minimizing batch effects and technical errors, thus facilitating the development of dynamic models that can infer the interactions between causal pathways in a quantitative manner. Additionally, integration of several genome-wide genomics approaches with the Replica Set method is feasible because a large population of age-synchronized animals is divided into a number of small populations.

Other methods have been previously developed to improve the throughput of *C. elegans* lifespan experiments, often focusing on adapting the traditional longitudinal approach (*i.e.* following the same set of animals over time) to automated observation and recording using common flatbed scanners<sup>38, 39</sup>, or more specialized equipment such as microfluidic plates<sup>40</sup>. The scanner-based approaches use light as a stimulus and compare sequentially captured images to determine alive/dead status based on movement for multiple plates at one time; while such approaches do not require proprietary scientific hardware, time involved in setting up the workflows may be substantial depending on the desired scale. Alternatively, lifespan experiments in custom microfluidic devices allow for in-depth phenotypic characterization of single animals over time, and without treatment to prevent progeny, but necessitate fabrication of the microfluidic plates and acquisition of associated microfluidic pumps and imaging equipment. In contrast, the Replica Set method, in combination with the software detailed here, allows greatly improved throughput using tools that are already common in laboratories working with *C. elegans*.

The WormLife software will be improved in the future to offer easier access to the statistical comparison, and compatibility with additional platforms. The most up-to-date documentation for the software can be found at the GitHub page, including installation instructions for platforms on which the software has been tested. A web-based version will also be developed to enable convenient access without the need to install any software.

In summary, the combination of the Replica Set method and the freely available software detailed here provides a powerful platform for improving the throughput and robustness of lifespan experiments and a broad range of survival-based assays (*e.g.* stress tolerance, toxicology studies, healthspan, etc.). Particularly when combined with functional genomics, this approach leverages the many benefits of the metazoan model system *C. elegans* for deciphering the myriad of genetic interactions that contribute to the progression of aging.

#### **ACKNOWLEDGMENTS:**

Funding for this work described in this manuscript was provided by: the University of Rochester Office of The Provost and the School of Medicine and Dentistry Dean's Office via the Health

Sciences Center for Computational Innovation (HSCCI); the Ellison Medical Foundation New Scholars in Aging Fellowship (AG-NS-0681-10) [www.ellisonfoundation.org](http://www.ellisonfoundation.org); Glenn Foundation for Medical Research (Glenn Award for Research in Biological Mechanisms of Aging PS#: 213633) [www.glennfoundation.org](http://www.glennfoundation.org); ARRA funding for faculty recruitment in Aging and Metabolism Research (P30 AG036489-01) [www.nih.gov](http://www.nih.gov), and by the National Institute On Aging of the National Institutes of Health under Award Number R01AG043421. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

#### DISCLOSURES:


The authors declare that they have no competing financial interests.

#### REFERENCES:

1. Timmons, L., Fire, A. Specific interference by ingested dsRNA [10]. *Nature*. **395** (6705), 854, doi: 10.1038/27579 (1998).
2. Kamath, R.S., Martinez-Campos, M., Zipperlen, P., Fraser, A.G., Ahringer, J. Effectiveness of specific RNA-mediated interference through ingested double-stranded RNA in *Caenorhabditis elegans*. *Genome Biology*. **2** (1), research0002.1-10, doi: 10.1186/gb-2000-2-1-research0002 (2000).
3. Winston, W.M., Sutherlin, M., Wright, A.J., Feinberg, E.H., Hunter, C.P. *Caenorhabditis elegans* SID-2 is required for environmental RNA interference. *Proceedings of the National Academy of Sciences*. **104** (25), 10565–10570 (2007).
4. Winston, W.M., Molodowitch, C., Hunter, C.P. Systemic RNAi in *C. elegans* requires the putative transmembrane protein SID-1. *Science*. **295** (5564), 2456–2459 (2002).
5. Grishok, A. RNAi mechanisms in *Caenorhabditis elegans*. *FEBS letters*. **579** (26), 5932–5939 (2005).
6. Ceron, J. *et al.* Toward Improving *Caenorhabditis elegans* Phenome Mapping With an ORFeome-Based RNAi Library. *Genome Research*. (14), 2162–2168, doi: 10.1101/gr.2505604.7 (2004).
7. Kamath, R.S. *et al.* Systematic functional analysis of the *Caenorhabditis elegans* genome using RNAi. *Nature*. **421** (6920), 231–237, doi: 10.1038/nature01278 (2003).
8. Samuelson, A. V, Carr, C.E., Ruvkun, G. Gene activities that mediate increased life span of *C. elegans* insulin-like signaling mutants. *Genes & Development*. **21** (22), 2976–94, doi: 10.1101/gad.1588907 (2007).
9. Petrascheck, M., Miller, D.L. Computational Analysis of Lifespan Experiment Reproducibility. *Frontiers in Genetics*. **8** (June), doi: 10.3389/fgene.2017.00092 (2017).
10. Samuelson, A. V, Klimczak, R.R., Thompson, D.B., Carr, C.E., Ruvkun, G. Identification of *Caenorhabditis elegans* Genes Regulating Longevity Using Enhanced RNAi-sensitive Strains. *Cold Spring Harbor Symposia on Quantitative Biology*. **LXXII**, 489–497, doi: 10.1101/sqb.2007.72.068 (2007).
11. R Core Team R: A Language and Environment for Statistical Computing. at <<https://www.r-project.org/>>.

12. Byerly, L., Cassada, R.C., Russell, R.L. The life cycle of the nematode *Caenorhabditis elegans*. *Developmental Biology*. **51** (1), 23–33, doi: 10.1016/0012-1606(76)90119-6 (1976).
13. Shi, C., Murphy, C.T. Mating Induces Shrinking and Death in *Caenorhabditis* Mothers. *Science*. **343** (6170), 536–540, doi: 10.1126/science.1242958 (2014).
14. Hodgkin, J. Male Phenotypes and Mating Efficiency in *CAENORHABDITIS ELEGANS*. *Genetics*. **103** (1), 43–64, at <<http://europepmc.org/articles/PMC1202023/?report=abstract>> (1983).
15. Kaplan, E.L., Meier, P. Nonparametric Estimation from Incomplete Observations. *Journal of the American Statistical Association*. **5318910** (282), 457–481, doi: 10.2307/2281868 (1958).
16. Mantel, N. Evaluation of survival data and two new rank order statistics arising in its consideration. *Cancer Chemotherapy Reports*. **50** (3), 163–170 (1966).
17. Rechavi, O. *et al.* Starvation-induced transgenerational inheritance of small RNAs in *C. elegans*. *Cell*. doi: 10.1016/j.cell.2014.06.020 (2014).
18. Larance, M. *et al.* Global Proteomics Analysis of the Response to Starvation in *C. elegans*. *Molecular & Cellular Proteomics*. **14** (7), 1989–2001, doi: 10.1074/mcp.M114.044289 (2015).
19. Vanfleteren, J.R., De Vreese, A., Braeckman, B.P. Two-Parameter Logistic and Weibull Equations Provide Better Fits to Survival Data From Isogenic Populations of *Caenorhabditis elegans* in Axenic Culture Than Does the Gompertz Model. *The Journals of Gerontology Series A: Biological Sciences and Medical Sciences*. **53A** (6), B393–B403, doi: 10.1093/gerona/53A.6.B393 (1998).
20. Johnson, D.W., Llop, J.R., Farrell, S.F., Yuan, J., Stolzenburg, L.R., Samuelson, A. V. The *Caenorhabditis elegans* Myc-Mondo/Mad Complexes Integrate Diverse Longevity Signals. *PLoS Genetics*. **10** (4), e1004278, doi: 10.1371/journal.pgen.1004278 (2014).
21. Ogg, S. *et al.* The fork head transcription factor DAF-16 transduces insulin-like metabolic and longevity signals in *C. elegans*. *Nature*. **389** (6654), 994–999, doi: 10.1038/40194 (1997).
22. Porta-de-la-Riva, M., Fontrodona, L., Villanueva, A., Cerón, J. Basic *Caenorhabditis elegans* Methods: Synchronization and Observation. *Journal of Visualized Experiments*. (64), 1–9, doi: 10.3791/4019 (2012).
23. Hansen, M., Hsu, A.L., Dillin, A., Kenyon, C. New genes tied to endocrine, metabolic, and dietary regulation of lifespan from a *Caenorhabditis elegans* genomic RNAi screen. *PLoS Genetics*. **1** (1), 0119–0128, doi: 10.1371/journal.pgen.0010017 (2005).
24. Van Raamsdonk, J.M., Hekimi, S. FUDR causes a twofold increase in the lifespan of the mitochondrial mutant *gas-1*. *Mechanisms of ageing and development*. **132** (10), 519–521 (2011).
25. Feldman, N., Kosolapov, L., Ben-Zvi, A. Fluorodeoxyuridine improves *Caenorhabditis elegans* proteostasis independent of reproduction onset. *PloS one*. **9** (1), e85964 (2014).
26. Aitlhadj, L., Stürzenbaum, S.R. The use of FUDR can cause prolonged longevity in mutant nematodes. *Mechanisms of ageing and development*. **131** (5), 364–365 (2010).
27. Kenyon, C., Chang, J., Gensch, E., Rudner, A., Tabtiang, R. A *C. elegans* mutant that lives twice as long as wild type. *Nature*. **366** (6454), 461–464, doi: 10.1038/366461a0 (1993).


28. Larsen, P.L., Albert, P.S., Riddle, D.L. Genes that regulate both development and longevity in *Caenorhabditis elegans*. *Genetics*. **139** (4), 1567–1583 (1995).
29. Shaw, W.M., Luo, S., Landis, J., Ashraf, J., Murphy, C.T. The *C. elegans* TGF-beta Dauer pathway regulates longevity via insulin signaling. *Current biology*. **17** (19), 1635–1645, doi: 10.1016/j.cub.2007.08.058 (2007).
30. Mukhopadhyay, A., Oh, S.W., Tissenbaum, H.A. Worming pathways to and from DAF-16/FOXO. *Experimental Gerontology*. **41** (10), 928–934, doi: 10.1016/j.exger.2006.05.020 (2006).
31. Lin, K., Dorman, J.B., Rodan, A., Kenyon, C. daf-16: An HNF-3/forkhead family member that can function to double the life-span of *Caenorhabditis elegans*. *Science*. **278** (5341), 1319–1322, doi: 10.1126/science.278.5341.1319 (1997).
32. Gandhi, S., Santelli, J., Mitchell, D.H., Stiles, J.W., Sanadi, D.R. A simple method for maintaining large, aging populations of *Caenorhabditis elegans*. *Mechanisms of ageing and development*. **12** (2), 137–150 (1980).
33. Hosono, R. Sterilization and growth inhibition of *Caenorhabditis elegans* by 5-fluorodeoxyuridine. *Experimental gerontology*. **13** (5), 369–373 (1978).
34. Mitchell, D.H., Stiles, J.W., Santelli, J., Sanadi, D.R. Synchronous growth and aging of *Caenorhabditis elegans* in the presence of fluorodeoxyuridine. *Journal of gerontology*. **34** (1), 28–36 (1979).
35. Anderson, E.N. *et al.* *C. elegans* lifespan extension by osmotic stress requires FUDR, base excision repair, FOXO, and sirtuins. *Mechanisms of ageing and development*. **154**, 30–42 (2016).
36. Garigan, D., Hsu, A.L., Fraser, A.G., Kamath, R.S., Ahringer, J., Kenyon, C. Genetic analysis of tissue aging in *Caenorhabditis elegans*: A role for heat-shock factor and bacterial proliferation. *Genetics*. **161** (3), 1101–1112 (2002).
37. Yu, S., Driscoll, M. EGF signaling comes of age: Promotion of healthy aging in *C. elegans*. *Experimental Gerontology*. **46** (2–3), 129–134, doi: 10.1016/j.exger.2010.10.010 (2011).
38. Mathew, M.D., Mathew, N.D., Ebert, P.R. WormScan: A technique for high-throughput phenotypic analysis of *Caenorhabditis elegans*. *PLoS ONE*. doi: 10.1371/journal.pone.0033483 (2012).
39. Stroustrup, N., Ulmschneider, B.E., Nash, Z.M., López-Moyado, I.F., Apfeld, J., Fontana, W. The *caenorhabditis elegans* lifespan machine. *Nature Methods*. **10** (7), 665–670, doi: 10.1038/nmeth.2475 (2013).
40. Xian, B. *et al.* WormFarm: A quantitative control and measurement device toward automated *Caenorhabditis elegans* aging analysis. *Aging Cell*. **12** (3), 398–409, doi: 10.1111/accel.12063 (2013).






### A. Traditional Method

- Limited # of sets/condition
- Same set followed over time
- Viability assessed by physical stimulus (poking)



### B. Replica Set Method

- Many sets per condition
- Each set scored once
- Viability assessed by adding liquid and poking



### C. 96-well *E. coli* liquid culture

### 24-well RNAi plate




Figure 3

[Click here to download Figure 3.tiff](#)




Figure 4

[Click here to download Figure Figure 4.tif](#)





Figure 5



Name of Material/ Equipment	Company	Catalog Number
IPTG (isopropyl beta-D-1-thigalactopyranoside)	Gold Bio	12481C100
FuDR (5-Fluoro-2'-deoxyuridine)	Alfa Aesar	L16497
24 Well Culture Plates	Greiner Bio-One	#662102
Retangular non-treated single-well plate, 128x86mm	Thermo-Fisher	242811
600 µL 96-well plates	Greiner Bio-One	#786261
2mL 96-well plates	Greiner Bio-One	#780286
Air-permeable plate seal	VWR	60941-086
96-pin plate replicator	Nunc	250520
bacto-peptone	VWR	90000-368
bacteriological agar	Affymetrix/USB	10906
C. elegans RNAi clone library in HT115 bacteria- Ahringer	Source Bioscience	C. elegans RNAi Collection (Ahringer)
C. elegans RNAi clone library in HT115 bacteria- Vidal	Source Bioscience	C. elegans ORF- RNAi Resource (Vidal)
WormLife- Software for Replica Set Survival Analysis	Samuelson Lab	N/A
L4440 Empty Vector Plasmid	Addgene	1654
Wormbase		
OASIS		
Graphpad Prism		



## Comments/Description

See also Kamath et. al, Nature 2003.

See also Rual et. al, Genome Research 2004. This library is also available from Dharmacon.

<https://github.com/samuelslab-urmc/wormlife>

<https://www.addgene.org/1654/>

<http://www.wormbase.org/>

<https://sbi.postech.ac.kr/oasis2/>

<https://www.graphpad.com/scientific-software/prism/>



1 Alewife Center #200  
Cambridge, MA 02140  
tel. 617.945.9051  
www.jove.com

## ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

*The Replica Set method is a high-throughput approach to quantitatively measure Caenorhabditis elegans lifespan*

Author(s):

*Adam B. Cornwell, Jesse Llop, Peter Salzman, Juilee Thakar, Andrew V. Samuelson*

Item 1 (check one box): The Author elects to have the Materials be made available (as described at <http://www.jove.com/author>) via: ☒ Standard Access ☐ Open Access

Item 2 (check one box):

- ☒ The Author is NOT a United States government employee.
- ☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.
- ☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

### ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: “**Agreement**” means this Article and Video License Agreement; “**Article**” means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; “**Author**” means the author who is a signatory to this Agreement; “**Collective Work**” means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; “**CRC License**” means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; “**Derivative Work**” means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; “**Institution**” means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; “**JoVE**” means MyJoVE Corporation, a Massachusetts corporation and the publisher of *The Journal of Visualized Experiments*; “**Materials**” means the Article and / or the Video; “**Parties**” means the Author and JoVE; “**Video**” means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4 and 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the “Open Access” box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.



## ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such

statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

9. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

10. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have



## ARTICLE AND VIDEO LICENSE AGREEMENT

full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's


expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

12. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

13. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to me one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

### CORRESPONDING AUTHOR:

Name:	<i>Andrew V. Samuelson, Ph.D.</i>	
Department:	<i>Biomedical Genetics</i>	
Institution:	<i>University of Rochester Medical Center</i>	
Article Title:	<i>The Replica Set method is a high-throughput approach to quantitatively measure Caenorhabditis elegans lifespan</i>	
Signature:		Date: <i>Dec. 30 2017</i>

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy of the document as a pdf on the JoVE submission site;
- 2) Fax the document to +1.866.381.2236;
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02139

For questions, please email [submissions@jove.com](mailto:submissions@jove.com) or call +1.617.945.9051

## DEPARTMENT OF BIOMEDICAL GENETICS

Andrew Samuelson, Ph.D.  
Research Associate Professor



Dear Dr. Bajaj, Ph.D.

I would like to thank you for the opportunity to submit a revised version of our manuscript entitled: "The Replica Set method: a high-throughput approach to quantitatively measure *Caenorhabditis elegans* lifespan" for your consideration for publication in JoVE. I also sincerely thank the reviewers and editors for their insightful comments and guidance, which has allowed us to improve and focus our revised manuscript.

In the revised manuscript we have addressed all of the major and minor concerns of both the editors and reviewers. As I mention in the detailed comments to the critique, some statements in the original manuscript were based on unpublished data that directly compares the accuracy, precision, and resiliency between the two methods, the findings of which are currently under revision at another journal (and beyond the scope of a methods paper). In hindsight, we recognize how some statements in our original submission didn't have adequate context, as they were based on these unpublished findings and thus would lead a reviewer to see them as over exaggerations or false equivalencies. In the revised manuscript we have either completely removed or significantly toned down these areas of previous concern. Additionally, we have added several tables to address separate concerns of the reviewer and editor. Lastly, we have expanded our discussion to more accurately compare and contrast the strengths and limitations of both methods. Overall, we have focused the revised manuscript on the actual methodology.

Thank you again for your time and consideration of our manuscript. We look forward to hearing from you.

Sincerely,

A handwritten signature in black ink, appearing to read "Andrew V. Samuelson".

Andrew V. Samuelson

## Detailed comments to the critique.

### **Editorial comments:**

*Changes to be made by the Author(s):*

*1. Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammar issues. The JoVE editor will not copy-edit your manuscript and any errors in the submitted revision may be present in the published version.*

We have proofed the manuscript for spelling and grammar issues.

*2. Please rephrase the Title to not be a sentence.*

We have changed the title to better match the style of other JoVE article titles.

*3. Please ensure that there are no crashed units in the manuscript: 17 g of agar instead of 17g agar, etc.*

We have corrected these instances.

*4. Please ensure that all text in the protocol section is written in the imperative tense as if telling someone how to do the technique (e.g., "Do this," "Ensure that," etc.). The actions should be described in the imperative tense in complete sentences wherever possible. Avoid usage of phrases such as "could be," "should be," and "would be" throughout the Protocol. Any text that cannot be written in the imperative tense may be added as a "Note." However, notes should be concise and used sparingly. Please include all safety procedures and use of hoods, etc.*

We have revised the protocol text.

*5. The Protocol should contain only action items that direct the reader to do something. Please move the discussion about the protocol to the Discussion.*

We have revised the protocol text. A few instances of non-directive statements remain for section headings (e.g. a brief description of the purpose of a protocol section) and for describing the expected outcome of a step.

*6. Please convert centrifuge speeds to centrifugal force (x g) instead of revolutions per minute (rpm).*

Mentions of centrifuge speed have been converted.

*7. Please revise the text to avoid the use of any personal pronouns (e.g., "we", "you", "our" etc.).*

Corrected.



*8. Lines 226-251 should be revised heavily.*

We have revised this section of the text and moved some portions to discussion.

*9. The Protocol should be made up almost entirely of discrete steps without large paragraphs of text between sections. Please simplify the Protocol so that individual steps contain only 2-3 actions per step and a maximum of 4 sentences per step.*

We have revised the protocol text.

*10. There is a 10-page limit for the Protocol, but there is a 2.75-page limit for filmable content. Please highlight 2.75 pages or less of the Protocol (including headings and spacing) that identifies the essential steps of the protocol for the video, i.e., the steps that should be visualized to tell the most cohesive story of the Protocol. Remember that non-highlighted Protocol steps will remain in the manuscript, and therefore will still be available to the reader.*

In the revised manuscript we have limited highlighting to 2.75 pages, which identifies the essential steps in the protocol.

*11. Please ensure that the highlighted steps form a cohesive narrative with a logical flow from one highlighted step to the next. Please highlight complete sentences (not parts of sentences). Please ensure that the highlighted part of the step includes at least one action that is written in imperative tense.*

Corrected.

*12. Please consider highlighting only the concrete experimental actions instead of the data analysis.*

We have done as requested and only highlight experimental actions in the revised manuscript.

*13. Please consider providing reaction set-ups and solution compositions as Tables in separate .xls or .xlsx files uploaded to your Editorial Manager account. These tables can then be referenced in the protocol text.*

We have done as the editor suggested and moved these sections to Table S2 in the revised manuscript.

*14. Please do not abbreviate journal titles.*

Corrected.

## **Reviewers' comments:**

### **Reviewer #1:**

#### *Manuscript Summary:*

*The replica set method is a valid and appropriate tool to define lifespan information. The wormlife software appears to be useful for interpreting this type of data, although this is not easily testable in the review. That said, the manuscript as written is misleading and makes highly over exaggerated claims that are not supported by previously published works and methodologies. The authors should rewrite the manuscript without any hype or misleading claims.*

We thank the reviewer for agreeing that the replica set method is an appropriate tool for measuring changes in *C. elegans* lifespan. We apologize for any claims that appear misleading or exaggerated. Some of the claims we made in the first submission were based on our unpublished data that is in revision for publication at another journal. In hindsight, we see how this could have caused confusion, but we were trying to strike a balance between presenting the methodology and comparing and contrasting the differences between the two methods without going into excessive detail. The reviewer is correct in pointing out areas where we overstepped and we sincerely thank them for their efforts to improve our manuscript. In the revised manuscript we have removed claims that are based on our own unpublished observations and results.

#### *Major Concerns:*

*There are several false equivalencies presented in this manuscript that inappropriately compare the replica set method to other lifespan studies. I do not understand why "traditional" is in quotations when referring to longitudinal assays.*

We have removed the quotations around traditional.

*The definition of a longitudinal lifespan experiment is an assessment of a population over the life course. The replica method described is NOT a longitudinal assay as animals are not followed over their entire lives.*

We agree completely. We did not mean to imply that the replica set method was a longitudinal assay.

*The abstract states "in the same amount of time without loss of data quality". I think the authors mean "over" the same amount of time for the experiment as this method takes significantly longer to set up.*

We have made the correction in the revised manuscript.

*Samples will naturally degrade (animals will die) at the same rate over the lifespan thus the data quality issue is not alleviated. If anything, using fewer animals (at later time points) makes statistical power measures more difficult.*

In the revised manuscript we have removed discussion about data quality and now focus solely on the appropriate statistical analysis for evaluating data generated using the replica set method.

*There are several instances where the authors simply present inaccurate information:*

*1. Lifespan is NOT a convenient surrogate measure of aging. If anything, it is the most difficult.*

We have removed “and convenient”.

*2. The authors state, "Older animals become largely paralyzed and mired in E. coli, while E. coli become an opportunistic pathogen (colonizing the lumen and packing the pharynx). Very old living animals can only be identified by subtle head movements. Thus, it is easy to classify a decrepit live animal as dead. In conjunction, a small population size makes a demographic analysis difficult to meaningless". However, these issues are actually exacerbated by this method. Again, I think this method is perfectly fine and having a methods paper on it is appropriate. But the comparison made is inaccurate.*

We respectfully disagree with the reviewer about ease of scoring. Having literally observed over one million animals by eye using the replica set method and tens of thousands of observations by the traditional approach, we can confidently say that it is easier to assess whether an animal is alive or dead via the replica set method.

We do apologize for the confusion about demographic analysis. Based on the reviewer's comment about focusing on the methodology, we believe that discussing the differences between the two methods in terms of demography is a distraction and therefore have removed all mention of demographic analysis in the revised manuscript.

*3. "Scoring at each time point is independent from the others. Thus, incorrectly scoring the viability of an animal at one-time point does not impact how populations will be scored at other time points". But this negates the utility of analysis of that inaccurate time point over the entire lifespan - how do you end up censoring a whole time point if it were deemed flawed?*

We apologize for the confusion, we realize in hindsight that we didn't provide adequate information to put that statement into the proper context. In short, in the revised manuscript we have removed mention of error/censoring.

However, to answer the reviewers concern: we have completed an *in silico* analysis that demonstrates how introducing error (e.g. incorrectly scoring viability or accidentally killing an animal) alters the perceived mean lifespan when using either method (in preparation for resubmission elsewhere). In the traditional approach, if there is an error in scoring (or accidental killing of an animal) it will significantly alter the perceived mean lifespan away from the true mean. In contrast, if one incorrectly scores viability for an animal when using the replica set method, it has almost no impact on mean lifespan (rather variance increases). We believe reporting all of this is beyond the scope of the current manuscript and have revised the manuscript accordingly.

4. *"Finally, approximately the same numbers of animals are scored at each point throughout the experiment, which solves a common demographic issue; specifically, at advanced time points with the traditional longitudinal method, only a few surviving animals are left to follow". This is absolutely incorrect and "solves" nothing with regard to power concerns for analysis. Animals in each replicate will age at the same rate, thus at the end of the lifespan the same issues of loss of statistical power persist. By only making use of 50 animals at the start of the experiment makes maximal lifespan (10% survival) analysis relying on 5 animals - regardless if you set up 10-time points (500 animals) there are only 50 animals being set up for the final time point.*

We thank the reviewer and have removed this from the revised manuscript, as implications for demographic analysis is not pertinent to describing the methodology.

5. *The MAJOR drawback of this method is the necessity to impair progeny production. Although this is discussed in the manuscript it is not accurately compared to other methods. It has been reported by several labs that the use of FUDR significantly alters lifespan. Similarly, the use of sterile strains can have genetic pleiotropies. If readers are to choose moving animals during reproduction, the replica plate method becomes a herculean task having to move adults across each of the time points.*

We agree with the reviewer that progeny production must be prevented. We mention this limitation within the discussion of the revised manuscript.

#### *Minor Concerns:*

1. *Figure 1 is not informative and should be removed. There is not any useful information in the figure as presented except that daf-16 has been reported a lot, and there would appear to be other genes reported less, but there is not any specifics presented.*

In the revised manuscript we have provided new supplemental tables (Table S1a, b). In this table we provide specifics for each study that was conducted and the number of gerogenes that were discovered (Table S1a), and a second (Table S1b) that lists each gerogene, the current number of studies associated with each (based on wormbase ws262), and whether it has been ascribed as a longevity gene, progeric, both, or neither (see point response to minor point 2 immediately below).

2. *Has gerogenes been approved by the CGC and wormbase?*

To the best of our knowledge, there is no standardized nomenclature for the classification of genes whose function alters how an organism ages. Currently the nomenclature that is typically used is actually rather confusing to a non-aficionado. As the reviewer is probably aware, genes that increase lifespan when inactivated/mutated are commonly referred to as "longevity genes" - yet the normal functions of these genes limit longevity. Conversely, genes that shorten lifespan and demonstrate other signs of premature aging when lost have been referred to as "progeric". Classifying a gene based on mutant phenotypes is confusing, but at this point has become entrenched within the field. Wormbase handles the issue by using rather vague terms like "lifespan variant", which we believe is rather imprecise- any gene that results in the premature

death of an animal could be considered a lifespan variant. We wanted to have a more precise term to encompass both longevity and progeric genes. "Aging genes" seems a poor choice as it either: 1) implies functional directionality opposite of longevity genes or 2) is itself imprecise as genes themselves do not actually age. "Gerogene" is a new term that Dr. Andrew Dillin and I coined, which more precisely classifies genes whose function alters how an organism ages (either positively or negatively). We believe this is a better classification than what is currently used within the field and intend to advocate for its usage. In the revised text we clarify that this is a new term.

*3. The authors should reference all 10 RNAi screens that have uncovered genes involved in lifespan. Although by my count there are at least 12 large scale screens that have been performed by the C. elegans research community.*

We thank the reviewer and in our revised manuscript we have included Table S1a, which lists all screens for genes involved in lifespan that are listed in Wormbase WS263. Note, studies that did not use the lifespan phenotype in the primary screen are not listed (e.g. changes in proteostasis). We hope that we have provided the proper credit for all previous large-scale lifespan studies and encourage the reviewer to check Table S1a to ensure we have not inadvertently missed a study.

## **Reviewer #2:**

### *Manuscript Summary:*

*The authors provide a detailed protocol for the Replica Set life span method to measure population survival of C. elegans in a high-throughput manner, as well as a web-based analysis interface to plot and analyze data resulting from this method and from "traditional" life span assays.*

### *Major Concerns:*

*None*

### *Minor Concerns:*

*- In the introduction, the authors should cite a recent analysis by Petraschek and Miller which described that most life span studies in C. elegans are likely underpowered considering the magnitude of change, which further support the use of methods such as the one presented herein, which allow convenient use of larger samples.*

We thank the reviewer for their insight and have made the suggested addition in the revised manuscript.

*- Point 1.1.1.3 When the agar has cooled enough but is still fluid- under 55°C but higher than 40°C- add 250 µL nystatin (40mg/mL) and 8mL streptomycin (25mg/mL). After allowing a few minutes for mixing, follow standard lab protocol for pouring plates. 1L is enough for approximately 80 6cm plates (12mL per plate), or 25 10cm plates (36mL per plate)." The authors should clarify*



*that the use of both nystatin and streptomycin is NOT part of making standard NGM, but rather an optional choice used by some labs doing life span assays to prevent contamination in this long-term assay.*

We have made the suggested change in the revised manuscript.

*- Line 137, syntax "E. coli does is"*

Fixed.

*- Point 2.1.1, some last allow hatching to occur on unseeded NGM plates*

We have made the suggested addition to the revised manuscript.

*- Line 219, the citation for the OASIS method I missing and must be added*

Fixed.

*- Line 504, unformat bold*

Fixed.

*- Line 617: revise syntax "The net result is throughput: the Replica Set method is at least an order of magnitude greater than the traditional approach"*

Fixed.

*- Line 635/36, remove bold format "most gerogenes remain poorly studied"*




We have corrected the revised manuscript to indicate that this is a heading for panel B of Figure 1.

*- Line 647: Either remove "age-synchronized isogenic" or add it in on line 642 - it is not different between the two methods and emphasis here suggest it is*

We have clarified the text in the revised manuscript.

*- Line 721 and below, another advantage of the traditional method that is not mentioned is that sterile strains or FUdR don't have to be used; while for the replica set assay this is indispensable. Given that FUdR can affect life span and life span related parameters (stress responses, proteostasis) and working in mutant backgrounds is never ideal, this substantive advantage of the traditional method should be clearly stated. Cite PMIDs 26854551, 21893079, 24465816*

We thank the reviewer for their insight and have made the suggested change in the revised discussion.



**Comi**



[1]

[2]

[3]



[1]

[2]

[3]



[1]

[2]

[3]

[4]

[5]



[1]

[2]

[3]

[4]



[1]

[2]

[3]

[4]

[5]

## **mon reagents- Agar plates for *C. elegans* growth and maintenance**

### **Standard NGM plate recipe (per 1 L):**

Add 1 L ultrapure water to a 2 L flask, followed by 17 g agar, 3 g NaCl, and 2.5 g bacto-peptone. Thoroughly mix on a stir plate with a sterilized stir bar, and then autoclave on a program for liquids.

After the autoclave run is complete, resume stirring on the stir plate at a medium speed. Using sterile technique add the following: 1 mL Cholesterol (5 mg/mL), 1 mL 1 M  $\text{CaCl}_2$ , 1 mL 1 M  $\text{MgSO}_4$ , and 25 mL 1 M  $\text{KPO}_4$ .

When the agar has cooled enough but is still fluid- under 55 °C but higher than 40 °C- add 250  $\mu\text{L}$  nystatin (40 mg/mL) and 8 mL streptomycin (25 mg/mL). After allowing a few minutes for mixing, follow standard lab protocol for pouring plates. 1 L is enough for approximately 80 6 cm plates (12 mL per plate), or 25 10 cm plates (36 mL per plate).

**Note:** The use of both nystatin and streptomycin is an optional choice to prevent contamination in long-term lifespan assays.

### **RNAi plate recipe (per 1 L):**

Add 1 L ultrapure water to a 2 L flask, followed by 17 g agar, 3 g NaCl, and 2.5 g bacto-peptone. Thoroughly mix on a stir plate with a sterilized stir bar, and then autoclave on a program for liquids.

After the autoclave run is complete, resume stirring on the stir plate at a medium speed. Using sterile technique add the following: 1 mL Cholesterol (5 mg/mL), 1 mL 1 M  $\text{CaCl}_2$ , 1 mL 1 M  $\text{MgSO}_4$ , and 25 mL 1 M  $\text{KPO}_4$ .

When the agar has cooled enough but is still fluid- under 55 °C but higher than 40 °C- add 1 mL carbenicillin (25 mg/mL) and 6 mL 0.2 g/mL IPTG (Isopropyl  $\beta$ -D-1-thiogalactopyranoside). After allowing a few minutes for mixing, follow standard lab protocol for pouring plates. 1 L is enough for approximately 80 6 cm plates (12 mL per plate), 25 10 cm plates (36 mL per plate), or 25 24-well plates (1.5 mL per well).

## **Common reagents- M9 Buffer Solution**

### **M9 buffer recipe (per 1 L):**

Add 0.75 L ultrapure water to a 1 L flask, with a sterile stir bar on a stir plate.

Add the following and allow to dissolve: 3 g monobasic  $\text{KH}_2\text{PO}_4$ , 6 g dibasic  $\text{Na}_2\text{HPO}_4$ , 5 g NaCl.

Add another 0.25 L ultrapure water. Allow to mix.

Distribute to autoclavable bottles of the desired volume. Autoclave on a program for liquids.

When completed, remove and allow to cool.

Once cool, add 1 mL per liter of 1M  $\text{MgSO}_4$  to each bottle.

## **Common reagents- Hypochlorite Solution**

### **recipe (10 mL):**

6.0 mL bleach

3.2 mL 5 N NaOH

0.8 mL MQ H<sub>2</sub>O

Bleach is light sensitive. Store for up to 2 weeks at RT.

## **Common reagents- Plates for bacterial culture**

### **LB + ampicillin + tetracycline agar plate recipe (per 1 L):**

Add 32 g LB agar to 1 L of ultrapure water with a sterile stir bar in a 2 L flask. Stir on a stir plate.

Once well-mixed, add 1.5 mL 2 N NaOH.

Autoclave on a liquid program. When autoclaving is complete, re-place on stir plate and allow to cool (with stirring) until reaching 55 °C.

Add 3 mL of 5 mg/mL tetracycline, and 1 mL of 50 mg/mL ampicillin. Allow to mix.

Use standard lab plate pouring procedures to dispense about 45 mL sterilized liquid LB agar mix per rectangular plate (Nunc Omnitray non-treated 128x86 mm or similar).

PLOS Genetics CC BY license: <https://www.plos.org/license>

Genes and Development CC-BY-NC license: <http://genesdev.cshlp.org/site/misc/terms.xhtml>



Click here to access/download  
**Supplemental Coding Files**  
Supplemental File 1.xlsx







Click here to access/download  
**Supplemental Coding Files**  
Supplemental File 2.xlsx





